Literature DB >> 22343392

Prevalence of fluoroquinolone-resistant Escherichia coli O25:H4-ST131 (CTX-M-15-nonproducing) strains isolated in Japan.

Shin-ichi Yokota1, Toyotaka Sato, Torahiko Okubo, Yasuo Ohkoshi, Tamaki Okabayashi, Osamu Kuwahara, Yutaka Tamura, Nobuhiro Fujii.   

Abstract

BACKGROUND: Fluoroquinolone-resistant and extended-spectrum β-lactamase (ESBL)-carrying multidrug-resistant Escherichia coli have become severely problematic. In particular, a lineage of multilocus sequence-type ST131 which belongs to O25:H4 and carries ESBL CTX-M-15 has spread worldwide.
METHODS: Fluoroquinolone-resistant E. coli strains were isolated from various clinical specimens in a commercial clinical laboratory in 2008 and 2009 in Hokkaido Prefecture, Japan.
RESULTS: Among 478 clinical isolates, 112 strains (23.4%) showed levofloxacin (LVX) resistance. About 80% of the fluoroquinolone-resistant strains (88 strains) showed common features, namely O25:H4-ST131, phylogenetic group B and the same mutation pattern in quinolone resistance-determining regions. Pulsed field gel electrophoresis patterns suggested numerous lineages of O25:H4-ST131. The fluoroquinolone-resistant strains, including strains of O25:H4-ST131 and other types, more frequently shared CTX-type ESBL genes than did fluoroquinolone-susceptible strains. The ESBL genes fell into the CTX-M-9 and CTX-M-2 groups. CTX-M-15 (CTX-M-1 group) was not found among any of the strains isolated in this study. Sitafloxacin showed markedly potent activity against E. coli isolates compared with LVX, ciprofloxacin and ulifloxacin.
CONCLUSION: The most prevalent fluoroquinolone-resistant strains of E. coli isolated in Hokkaido Prefecture, Japan, are O25:H4-ST131. However, similar to other areas of Japan, the ST131 clones represent distinct lineages from the general worldwide dispersal of multidrug-resistant clones which carry CTX-M-15.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343392     DOI: 10.1159/000336129

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  10 in total

Review 1.  Escherichia coli ST131, an intriguing clonal group.

Authors:  Marie-Hélène Nicolas-Chanoine; Xavier Bertrand; Jean-Yves Madec
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

2.  Contribution of Novel Amino Acid Alterations in PmrA or PmrB to Colistin Resistance in mcr-Negative Escherichia coli Clinical Isolates, Including Major Multidrug-Resistant Lineages O25b:H4-ST131-H30Rx and Non-x.

Authors:  Toyotaka Sato; Tsukasa Shiraishi; Yoshiki Hiyama; Hiroyuki Honda; Masaaki Shinagawa; Masaru Usui; Koji Kuronuma; Naoya Masumori; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Antimicrob Agents Chemother       Date:  2018-08-27       Impact factor: 5.191

3.  Tigecycline Nonsusceptibility Occurs Exclusively in Fluoroquinolone-Resistant Escherichia coli Clinical Isolates, Including the Major Multidrug-Resistant Lineages O25b:H4-ST131-H30R and O1-ST648.

Authors:  Toyotaka Sato; Yuuki Suzuki; Tsukasa Shiraishi; Hiroyuki Honda; Masaaki Shinagawa; Soh Yamamoto; Noriko Ogasawara; Hiroki Takahashi; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Antimicrob Agents Chemother       Date:  2017-01-24       Impact factor: 5.191

4.  Role of homologous recombination in adaptive diversification of extraintestinal Escherichia coli.

Authors:  Sandip Paul; Elena V Linardopoulou; Mariya Billig; Veronika Tchesnokova; Lance B Price; James R Johnson; Sujay Chattopadhyay; Evgeni V Sokurenko
Journal:  J Bacteriol       Date:  2012-11-02       Impact factor: 3.490

5.  Escherichia coli sequence type 131 is a dominant, antimicrobial-resistant clonal group associated with healthcare and elderly hosts.

Authors:  Ritu Banerjee; Brian Johnston; Christine Lohse; Stephen B Porter; Connie Clabots; James R Johnson
Journal:  Infect Control Hosp Epidemiol       Date:  2013-02-13       Impact factor: 3.254

6.  The role of Sequence Type (ST) 131 in adult community-onset non-ESBL-producing Escherichia coli bacteraemia.

Authors:  Yi-Hui Wu; Ming-Fang Cheng; Chung-Hsu Lai; Hsi-Hsun Lin; Chih-Hsin Hung; Jiun-Ling Wang
Journal:  BMC Infect Dis       Date:  2014-11-07       Impact factor: 3.090

Review 7.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

8.  Pathogenic Lineage of mcr-Negative Colistin-Resistant Escherichia coli, Japan, 2008-2015.

Authors:  Toyotaka Sato; Akira Fukuda; Yuuki Suzuki; Tsukasa Shiraishi; Hiroyuki Honda; Masaaki Shinagawa; Soh Yamamoto; Noriko Ogasawara; Masaru Usui; Hiroki Takahashi; Satoshi Takahashi; Yutaka Tamura; Shin-Ichi Yokota
Journal:  Emerg Infect Dis       Date:  2016-12       Impact factor: 6.883

9.  Mechanism of Reduced Susceptibility to Fosfomycin in Escherichia coli Clinical Isolates.

Authors:  Yasuo Ohkoshi; Toyotaka Sato; Yuuki Suzuki; Soh Yamamoto; Tsukasa Shiraishi; Noriko Ogasawara; Shin-Ichi Yokota
Journal:  Biomed Res Int       Date:  2017-01-19       Impact factor: 3.411

10.  Isolation of Human Lineage, Fluoroquinolone-Resistant and Extended-β-Lactamase-Producing Escherichia coli Isolates from Companion Animals in Japan.

Authors:  Toyotaka Sato; Shin-Ichi Yokota; Tooru Tachibana; Satoshi Tamai; Shigeki Maetani; Yutaka Tamura; Motohiro Horiuchi
Journal:  Antibiotics (Basel)       Date:  2021-11-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.